Investorideas.com newswire, breaking biotechnology and pharma news

Thursday, June 21, 2012

Biopharmaceutical Stock Alert: Onyx Pharmaceuticals (NASDAQ: ONXX) Big Moves on FDA Positive Vote

New York, New York - June 21, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), one of the NASDAQ’s top gainers, trading at $62.18, up $17.60 or (39.48%) as of 11:14AM EDT on over 16 Million shares. The stock has a morning high of $63.22.
The Company announced yesterday that the U.S. FDA's Oncologic Drugs Advisory Committee (ODAC) determined by a vote of 11-0 [with 1 abstention] that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of Kyprolis� (proposed brand name for carfilzomib). Onyx is developing Kyprolis for use in multiple myeloma across a variety of treatment lines.
Investorideas.com Newswire About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/ Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/ Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech stocks at the Biotech stocks Directory and biotech news and research at www.biotechindustrystocks.com
Become an Investorideas.com Member
http://www.investorideas.com/ membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Wednesday, June 20, 2012

Biotech Stock Breaking News: Sirona Biochem (TSX-V: SBM, OTC: SRBCF) Announces Primate Results for SGLT Inhibitor for Type 2 Diabetes

Vancouver, British Columbia - June 20, 2012 (Investorideas.com Newswire) Sirona Biochem Corp. ( TSX-V: SBM , OTC: SRBCF, Frankfurt: ZSB), announced today results from a preclinical study of its sodium glucose transporter (SGLT) inhibitor in monkeys. When administered orally, Sirona Biochem’s SGLT inhibitor, SBM-TFC-039, triggered glucosuria in a dose-dependent manner. In addition, the glucosuria effect was robust for the full 24 hours studied.

"At the recent American Diabetes Association meeting in Philadelphia, it was apparent that SGLT inhibitors are a potentially ground-breaking treatment for Type 2 diabetes," said Dr. Howard Verrico, President and CEO of Sirona Biochem. "Preclinical results of our SGLT inhibitor, SBM-TFC-039, in multiple species have consistently demonstrated its efficacy and we are exploring data that may differentiate SBM-TFC-039 from the other SGLT inhibitors in development," he added.
SBM-TFC-039 is an SGLT inhibitor drug candidate for Type 2 diabetes. In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.
SBM-TFC-039 has been tested acutely and chronically in a rodent diabetic model, in addition to the latest study in primates. In those tests, SBM-TFC-039 has consistently demonstrated a glucose-lowering effect in a dose-dependent manner.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Published at the Investorideas.com Newswire
Disclaimer http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com was not compensated for this news report

Tuesday, June 19, 2012

Biotech Stock News Alert;Aethlon Medical (OTC: AEMD) Announces Notice of Allowance of U.S. Patent Application

SAN DIEGO - June 19, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the U.S. Patent and Trademark Office (USPTO) has given the Company a Notice of Allowance for U.S. Patent Application No. 12/282152 entitled "Extracorporeal Removal of Microvesicular Particles." The patent grants Aethlon the exclusive right to remove immune suppressive microvesicular particles, which include but are not limited to exosomes, from the circulation of treated patients. The patent describes a method to bind and capture immune suppressive microvesicular particles from blood with a medical filtration device containing single or multiple affinity agents, which can include antibodies, aptamers, beads, lectins, proteins, or other compounds that adhere to microvesicles. The USPTO further notified the Company that it has calculated a Patent Term Adjustment of 452 days on the Notice of Allowance.
Investorideas.com Newswire "This patent allowance provides a cornerstone that reinforces our opportunity to establish a dominant market position in the therapeutic targeting of immunosuppressive exosomes," stated Jim Joyce, Chairman and CEO at Aethlon Medical. The Aethlon Hemopurifier�, which is a first-in-class device being advanced in Hepatitis C care, has demonstrated the ability to capture a broad-spectrum of immune suppressive exosomes underlying cancer. A therapy that could inhibit exosome proliferation would fulfill a major unmet medical need as corresponding drug therapies have yet to emerge.

In cancer, exosomes have recently emerged to become a vital therapeutic target as they play an instrumental role in promoting tumor progression by inducing programmed cell death of anticancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. The particles also seed the spread of tumor metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.
Circulating microvesicles or exosomes have also been discovered to have immunosuppressive roles in infectious disease and may accelerate the pathogenesis of other disease conditions as they have been reported to induce or amplify inflammatory and pathological conditions including, cardiovascular disease, hypertension, neurodegenerative disorders, diabetes, and rheumatic diseases. Beyond its cancer and infectious disease treatment initiatives, Aethlon is studying the deleterious role of exosomes in sepsis through a contract with the Defense Advanced Research Projects Agency (DARPA).
In addition to being known as exosomes, microvesicles have been referred to as epididimosomes, argosomes, exosome-like vesicles, microparticles, promininosomes, prostasomes, dexosomes, texosomes, dex, tex, archeosomes and oncosomes.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Wednesday, June 13, 2012

Pharma Stocks Dominate NASDAQ Top Percentage Gainers: ARNA, DNDN, HZMP, RPTP

New York, New York - June 13, 2012 (InvestorIdeas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an alert on the top percentage gainers for morning trading June13th. Four of the five top gainers, ARNA, DNDN, HZMP, RPTP, are pharma stocks.
Arena Pharmaceuticals, Inc. (NasdaqGS: ARNA) is trading up at $8.30, gaining $0.42(5.33%) 11:08AM EDT on over 25 Million shares with a high of $8.65. Commentary was issued on the stock yesterday on its participation in the anti obesity market.
Dendreon Corp. (NasdaqGS DNDN) is trading at $6.66, up 0.41(6.56%) 11:11AM EDT, with a high of $6.98 on volume of over 8 million shares.
Horizon Pharma, Inc. (NasdaqGM: HZNP) is trading up at $4.58, gaining 0.37(8.79%) 11:13AM EDT with a morning high of $4.73 on over 1 Million shares.
Raptor Pharmaceuticals Corp. (NasdaqGM :RPTP) is up, trading at $5.8350, jumping $0.3950 or (7.26%) 11:14AM EDT with a high of $6.15 in earlier trading on volume of over 2.7 Million shares. The Company reported yesterday that Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, will present an overview of the Company at the 2012 Wells Fargo Securities Healthcare Conference in Boston, MA at the InterContinental Hotel. Raptor's Presentation will take place on Tuesday, June 19, 2012 beginning at 3:30 p.m ET.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech,   China  stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech and pharma stocks at the Biotech stocks Directory
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Medical Device Stock to Watch; Aethlon Medical (AEMD) Chairman and CEO Discusses Melanoma Exosomes

New York, New York - June 13, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a news alert and company snapshot for Aethlon Medical (OTCBB:AEMD) , following news issued yesterday by the Company . Featuring commentary authored by Chairman and CEO, Jim Joyce on "Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis".
Aethlon Medical (OTCBB:AEMD) develops medical devices to address needs in cancer, infectious disease, and other life-threatening conditions.
"Our first research into cancer-secreted exosomes was driven by the curiosity that exosomes seemed to carry a unique high mannose signature that is found on the surface of glycoproteins that coat infectious viral pathogens. This signature happened to be the targeted binding site of the affinity agent immobilized in our Hemopurifier®, and provides the basis for our ability to selectively capture HCV, HIV, and a broad-spectrum of other viruses. In well-studied viruses such as HIV, we knew that surface glycoproteins can shed to trigger apoptosis or programmed cell death of immune cells. Therefore, it made sense to us that exosomes might have these same immunosuppressive properties. However, at the time we initiated our research, the medical community consensus was that exosomes were nothing more than cellular trash bags with no meaningful biologic function. In fact, there were only a handful of researchers with exosome focused research programs. This is no longer the case. Many cancer research institutes are now pursuing exosome driven initiatives as cancer-secreted exosomes have since been verified to play a significant role in the invasion of the immune system in cancer patients. Additionally, researchers now understand how exosomes contribute to the development of tumor angiogenesis as a mechanism for cancer to survive. The harmful role of exosomes is also being identified in other life threatening conditions, including sepsis, a disease we are studying under contract with the Defense Advanced Research Projects Agency (DARPA).
To date, we have demonstrated the ability to capture exosomes underlying a variety of cancers. As related to the discoveries by the Weill Cornell team, we fortuitously disclosed in September of 2010 that our Aethlon Hemopurifier® was able to capture exosomes derived from individuals with metastatic melanoma in a pre-clinical study. At present, we are fully focused on participating in a response to a new DARPA contract opportunity, expanding our HCV treatment studies, and preparing the resubmission of a investigational device exemption to FDA. Once these objectives have been advanced, we plan to discuss a potential melanoma treatment study that a U.S. based cancer research institute has proposed to conduct as a result of the Weill Cornell discoveries."
Full News:
http://www.investorideas.com/CO/AEMD/news/2012/06121.asp
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech stocks at the Biotech stocks Directory
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure investorideas.com is compensated by AEMD for news publication at Investorideas.com and syndicated partners: four thousand eight hundred fifty for six months
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Tuesday, June 12, 2012

Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis

SAN DIEGO - June 12, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Investorideas.com Newswire Last week, Medical News Today reported on a cancer research discovery that reinforces the potential importance of our therapeutic endeavors. For more than a century, cancer researchers have understood that certain forms of cancer only spread to specific, preferred organs. However, the mechanism underlying the spread of organ specific metastasis (the "soil and seed" theory of 1889) had remained unknown. Based on new findings published and now available online in the journal Nature, researchers have identified that circulating cancer-secreted particles known as "exosomes" play a significant role in fueling the metastatic invasion of preferred organs. The paper concludes that exosomes offer promise for new therapeutic directions in the metastatic process.
We applaud and appreciate this ground breaking research as our Hemopurifier� has been validated to capture the form of cancer-secreted exosomes referenced in the publication. The same Hemopurifier� that we have been advancing with promising results in the treatment of hepatitis c (HCV) infected individuals.
In the study, researchers were interested to see if exosomes budding from melanoma actually participated in the course of the cancer. The answer was yes, and to a great extent. The researchers identified that melanoma cancer cells released "exosome" vesicles (microscopic particles like "bubbles" that are filled with many different molecules such as proteins and nucleic acids) that travel to the bone, liver, lung and brain. This cellular material fuses with targeted organs and establishes the environment to spread tumor cells. The researchers also reported that cancer-secreted exosomes triggered inflammation, promoted leaky blood vessels and educated bone marrow progenitor cells to participate in the metastatic cascade. The discoveries were led by a team from the Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, with collaborative support from researchers at MD Anderson Cancer Center, Lawrence Berkeley National Laboratory, the National Cancer Institute, and the US National Institutes of Health.
Dr. Hector Peinado, the lead author of the study was quoted to say: "If, in the future, we were able to find a way to control the education of bone marrow cells, as well as the release and content of tumor exosomes in cancer patients, we would be able to curtail and reduce the spread of cancer, and improve the patient's quality of life and survival." At present, I am not aware of another therapeutic strategy beyond our Hemopurifier� that offers to inhibit or eliminate the presence of cancer-secreted exosomes.
The Weill-Cornell researchers also identified that exosome protein levels in circulation predicted disease stage, prognosis, and survival in subjects with metastatic disease. When they compared circulating exosomes taken from patients with different stages of melanoma, they found that stage IV patients displayed much higher exosome protein levels as compared with earlier stage melanoma patients. If disease had not yet metastasized, exosomes were not present in circulation. The researchers also noted that stage IV patients with a lower presence of exosomes tended to have longer survival than stage IV patients with higher exosome protein content. Again, reinforcing the therapeutic potential of a device that could inhibit or eliminate exosomes from circulation.
Our first research into cancer-secreted exosomes was driven by the curiosity that exosomes seemed to carry a unique high mannose signature that is found on the surface of glycoproteins that coat infectious viral pathogens. This signature happened to be the targeted binding site of the affinity agent immobilized in our Hemopurifier�, and provides the basis for our ability to selectively capture HCV, HIV, and a broad-spectrum of other viruses. In well-studied viruses such as HIV, we knew that surface glycoproteins can shed to trigger apoptosis or programmed cell death of immune cells. Therefore, it made sense to us that exosomes might have these same immunosuppressive properties. However, at the time we initiated our research, the medical community consensus was that exosomes were nothing more than cellular trash bags with no meaningful biologic function. In fact, there were only a handful of researchers with exosome focused research programs. This is no longer the case. Many cancer research institutes are now pursuing exosome driven initiatives as cancer-secreted exosomes have since been verified to play a significant role in the invasion of the immune system in cancer patients. Additionally, researchers now understand how exosomes contribute to the development of tumor angiogenesis as a mechanism for cancer to survive. The harmful role of exosomes is also being identified in other life threatening conditions, including sepsis, a disease we are studying under contract with the Defense Advanced Research Projects Agency (DARPA).
To date, we have demonstrated the ability to capture exosomes underlying a variety of cancers. As related to the discoveries by the Weill Cornell team, we fortuitously disclosed in September of 2010 that our Aethlon Hemopurifier� was able to capture exosomes derived from individuals with metastatic melanoma in a pre-clinical study. At present, we are fully focused on participating in a response to a new DARPA contract opportunity, expanding our HCV treatment studies, and preparing the resubmission of a investigational device exemption to FDA. Once these objectives have been advanced, we plan to discuss a potential melanoma treatment study that a U.S. based cancer research institute has proposed to conduct as a result of the Weill Cornell discoveries.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
All financial disclosures, anticipated revenue recognition amounts and other information related to the financial results and operations of the Company set forth above are unaudited and are subject to year-end audit adjustments and footnote disclosures.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Monday, June 4, 2012

Biotech Stock to Watch; Cleveland BioLabs (Nasdaq:CBLI) Big Moves on News of GLP Efficacy Study With Radiation Countermeasure CBLB502

New York, New YorkJune 4, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for
Cleveland BioLabs, Inc. (Nasdaq:CBLI), making gains of $0.68 or (53.54%) to trade at $1.95 12:36PM EDT on over 2.5 Million shares. The stock has a day’s high of $2.40.

The Company reported today strong survival results for its randomized, blinded, placebo-controlled efficacy study of CBLB502 in 179 non-human primates (NHPs) conducted under Good Laboratory Practice (GLP) with elements of Good Clinical Practice (GCP), as required by the U.S. Food and Drug Administration's (FDA) Animal Rule. The study demonstrated with a high degree of statistical significance the dose-response relationship between the administration of CBLB502 and the survival of lethally irradiated animals, the study's primary endpoint.

Your browser may not support display of this image.

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a direct acting anticancer agent. The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute of Australia and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas


Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp

Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

Become an Investorideas.com Member

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source www.Investorideas.com